MarketResearch.Biz announces publication of its most recently generated research report titled, “Europe Erythropoietin Market by Product Type (Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa, Other Product Types), Drug Class (Biologics, and Biosimilar), Indication (Cancer, Hematology, Renal Diseases, Neurology) and Country (Germany, UK, France, Italy, Spain, Russia, Rest of Europe) – Europe Forecast to 2030.”, which offers a holistic view of the Europe erythropoietin market through systematic segmentation that covers every aspect of the target market. The first five-year cumulative revenue (2020–2024) is projected to be over US$ 14.1 Bn, which is estimated to increase moderately over the latter part of the five-year forecast period.
Erythropoietin (EPO) is a hormone that is produced primarily by the kidneys, with small amounts created by the liver. Erythropoietin is an essential protein hormone that red blood cells (erythrocytes) produce. The red blood cells themselves transport oxygen to all bodily tissues. This hormone is synthesized in the kidneys, and its secretion is regulated by the amount of oxygen delivered to an organ. Erythropoietin is one of the first drugs produced through recombinant DNA technology, and is widely used in situations where the production of red blood cells is insufficient. Erythropoietin is essential for the production of red blood cells because it is necessary for the survival, proliferation and differentiation of erythroid progenitor cells in bone marrow. In the late stage of red blood cell differentiation, the receptor of erythropoietin is down-regulated, with the hormone being no longer necessary for a cell’s survival.
Europe Erythropoietin Market: Market Dynamics
The rising prevalence of cancer, ESRD (end-stage renal disease) and HIV has largely contributed to the increase in the demand for EPO drugs. Approximately 20% of cancer/HIV patients and approximately 70% of ESRD patients receive chemotherapy, which usually leads to anemia in such patients and therefore requires appropriate EPO treatment. This is the main revenue-generating factor in the erythropoietin market.
The outbreak of the COVID-19 pandemic has severely affected various manufacturing and supply chain operations in various industries including the healthcare industry. Most erythropoietin drug manufacturers stated that the temporarily interrupted drug supply subsequently led to a slowdown/suspension of the corresponding business, which had a negative impact on the industry.
The expiration of patents for major biological agents over the next few years will create opportunities for erythropoietin biosimilars to enter the market. For example, Amgen’s Epogen patent expired in 2018, which provided a huge opportunity for other companies to enter the erythropoietin industry. Hence, it is expected that there will be an increase in the number of new entrants investing in this sector, resulting in subsequent revenue growth.
Europe Erythropoietin Market: Market Forecast
The comprehensive research report comprises a complete forecast of the Europe Erythropoietin market based on factors affecting the market and their impact in the foreseeable future. According to the forecast projections, revenue from the Europe Erythropoietin market is estimated to expand at a moderate CAGR of 8.4% during the forecast period.
Europe Erythropoietin Market: Segmental Snapshot
The market report has been segmented on the basis of component product type, drug class, indication, and country. The Product Type segment includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, other product types. The drug class segment includes biologics, & biosimilar. Indication segment includes cancer, hematology, renal diseases, neurology. The country covered in the analysis are Germany, UK, France, Italy, Spain, Russia, Rest of Europe
By product type: The epoetin-alfa segment is expected to register a CAGR of over 8.8%, thereby accounting for highest revenue share among the product type segments.
By drug class: The biosimilar segment is expected to register a CAGR of over 8.9% over the forecast period, thereby accounting for highest revenue share among the drug class segments.
By indication: The renal diseases segment is expected to register a CAGR of over 8.5% over the forecast period, thereby accounting for highest revenue share among the indication segments.
By country: The market in Germany accounted for highest revenue share in the Europe Erythropoietin market in 2020, and is estimated to register a CAGR of over 9.1% between 2020 and 2030.
Europe Erythropoietin Market: Competitive Analysis
The research report on the Europe Erythropoietin market includes profiles of major companies such as Johnson & Johnson, Roche Holding AG, Pfizer Inc. (Hospira), Amgen, Inc, Kirin Holdings Co., Ltd. (Kyowa Hakko Kirin), Teva Pharmaceutical Industries Ltd, LG Corp. (LG Life Sciences Ltd.), Intas Pharmaceuticals Ltd, Biocon Ltd., Emcure Pharmaceuticals.
The Europe Erythropoietin Market: Europe Industry, Size, Share, Growth, Trends, and Forecast, 2020–2030 report has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the Europe Erythropoietin Market for 2020–2030.
MarketResearch.biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. MarketResearch.biz offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.
Like us on Facebook: https://www.facebook.com/marketresearch.biz
Follow on Twitter+: https://twitter.com/PrudourResearch
420 Lexington Avenue, Suite 300
New York City, NY 10170,
Email ID: email@example.com